Targeting a systolic blood pressure below 130 mm Hg was associated with a 21% decreased risk of all-cause mortality among patients with stage 3 to 4 chronic kidney disease, a meta-analysis found.
In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
A combination of intravenous lidocaine and ketorolac was found to be superior to IV lidocaine alone and comparable with IV ketorolac alone for alleviating suspected renal colic pain.
For nondiabetic CKD patients taking statins, targeting an intensive SBP goal of less than 120 mm significantly reduced the risks for all-cause and cardiovascular mortality by 56% and 71%, respectively, study finds.
